Menogon HP (highly purified menotropin) is a specialized fertility medication. Its use is focused on supporting patients with conditions characterized by infertility in women and men. It is applied across domains where additional symptomatic support for reproductive function is needed, helping to manage conditions characterized by systemic imbalance.

The medication is commonly used across conditions presenting with episodic or fluctuating symptom patterns, such as anovulation and hypogonadotropic hypogonadism. This is why it is often used when symptoms intensify and supportive relief is needed.

Key Therapeutic Benefits

Menogon HP may assist with the symptom cluster related to a lack of hormonal stimulation, contributing to easing the overall burden of hormonal deficiency symptoms. This assists with maintaining functional stability and supports patients during episodes of heightened discomfort. It is also relevant when additional management is required in contexts involving Assisted Reproductive Technologies (ART).

Quick Fact: Supports patients with symptoms linked to organ-specific functional stress

Official Eligibility and Non-Eligibility for Menogon HP

Based on authoritative regulatory documents, the use of Menogon HP (Menotropin) is subject to specific eligibility requirements and formal contraindications. Treatment is intended for patients requiring gonadotropin therapy for specific secondary fertility issues, such as women with anovulation (including Polycystic Ovarian Disease) who have not responded to clomiphene citrate, and those undergoing controlled ovarian hyperstimulation for Assisted Reproductive Technologies (ART). It is also approved for specific male infertility conditions.

Populations Who Must Not Use (Contraindicated)

Menogon HP is strictly contraindicated for several groups to avoid risk or ineffectiveness. This includes individuals with a documented hypersensitivity to the active substance or excipients, as well as those who are pregnant or breastfeeding.

Contraindicated conditions include primary ovarian failure (premature menopause) or primary testicular failure. Use is also prohibited in the presence of certain sex-hormone-dependent tumors (e.g., ovarian, uterine, or breast carcinoma), tumors of the pituitary gland or hypothalamus, and undiagnosed abnormal vaginal bleeding. Women with ovarian cysts or enlarged ovaries not due to Polycystic Ovarian Disease must not use this medicine.

Eligibility Restrictions

Treatment should only be initiated after a thorough evaluation and correction of untreated non-gonadal endocrinopathies (such as thyroid or adrenal gland issues). The product is not intended for use in the pediatric or elderly populations.

Interactions with other medicines and products

The official interaction profile for Menogon HP is defined by the regulatory information documented in government prescribing labels. The primary statement across multiple government-approved sources is that no formal human drug-drug interaction studies have been conducted for menotropin.

Consequently, there is no established data regarding potential pharmacokinetic interactions, such as those involving metabolic enzymes (like CYP450), or transporter-mediated effects. Similarly, no formal pharmacodynamic interactions are documented to describe additive or synergistic effects with co-administered medicines. No substance is officially listed to cause exposure-altering effects, such as increasing or decreasing menotropin concentration.

This lack of established systemic interaction data leads to a specific restriction concerning product handling: The reconstituted solution must not be physically mixed with any other medicinal product in the same syringe or container for administration, due to the absence of compatibility studies. This is a mandatory constraint related to the product’s preparation.

Furthermore, interactions with food, alcohol, and herbal products are also not formally established in regulatory documents. The official prescribing information also notes a data limitation in specific patient groups: pharmacokinetic and interaction data in patients with renal insufficiency or hepatic insufficiency have not been studied or established.

️ Targeted Gonadotropin Receptor Agonism

The primary mechanism of Menogon HP involves agonism at two crucial targets: the Follicle-Stimulating Hormone Receptor (FSHR) and the Luteinizing Hormone/Choriogonadotropin Receptor (LHCGR), which are G-protein coupled receptors found on gonadal cells. By binding to and activating these peripheral receptors, the medication initiates the necessary signal transduction cascades required for gonadal function.

Dual-Signal Synergy and the Steroidogenesis Pathway

Menotropin's mechanism is defined by its dual hormonal activity, providing both FSH and LH signals simultaneously, which is required for the complete activation of the Steroidogenesis Pathway. The FSH component drives cellular proliferation, while the LH component stimulates the production of essential androgen precursors in adjacent cells. This synergistic action provides the complete hormonal signal required for gonadal function by promoting both gamete development and sex hormone synthesis.

️ Mechanistic Constraint by Target Tissue Integrity

The effectiveness of this agonistic mechanism is entirely dependent on the presence of functional FSHR and LHCGR on responsive gonadal tissue. The drug provides an exogenous agonistic signal, and its action is limited in situations where the target tissue is non-functional or severely damaged (primary gonadal failure), demonstrating a direct mechanism limitation tied to receptor availability.

How to use Menogon HP: Official Administration Guidelines

Menogon HP (menotropins for injection) is administered by subcutaneous injection once daily, strictly under the supervision of a physician familiar with infertility treatment procedures.

Dosing and Preparation Requirements

Administration Scope	Official Guideline
Route of Administration	Subcutaneous (SC) injection.
Initial Daily Dose	Generally 225 International Units (IU) daily for the first five days.
Dose Adjustment	Adjustments are made after five days and by no more than 150 IU at each change.
Maximum Daily Dose	The daily dose must not exceed 450 IU.
Preparation	Reconstitute the lyophilized powder with the specified diluent (e.g., 1 mL of sterile saline) immediately prior to use. Do not shake the vial; gently swirl until dissolved.
Missed Dose Rule	Do not double the next dose to compensate for a missed dose.

Procedural Steps

• Rotation: The injection site should be rotated daily to prevent skin irritation.
• Monitoring: Dosage adjustments are based on the patient's ovarian response, as determined by ultrasound evaluation of follicular growth and serum estradiol levels.
• hCG Withholding: If monitoring on the final day of menotropins therapy indicates an increased risk of ovarian hyperstimulation syndrome (such as abnormally enlarged ovaries), the subsequent dose of human chorionic gonadotropin (hCG) must be withheld.
• Pen Use: For a ready-to-use pen, air bubbles must be removed (pen bleeding) before the first use. After injecting, the button must be held down for a specific time (e.g., eight seconds) to ensure full dose delivery.

Menogon HP: Recent Clinical Evidence

Menogon HP (highly purified Human Menopausal Gonadotropin, HP-hMG) is a fertility medication containing a 1:1 ratio of Follicle-Stimulating Hormone (FSH) and Luteinizing Hormone (LH) activity. The LH activity is derived primarily from Human Chorionic Gonadotropin (hCG), which has a longer half-life than natural LH.

Use in Controlled Ovarian Stimulation (COS)

HP-hMG is used to induce the development of multiple follicles as part of Assisted Reproductive Technologies (ART), such as In Vitro Fertilization (IVF). Comparative studies often assess HP-hMG against recombinant FSH (rFSH), which contains FSH activity only.

Study Comparison	Key Findings Observed
HP-hMG vs. rFSH (MERiT/MEGASET)	Comparable ongoing pregnancy rates were observed, establishing non-inferiority for HP-hMG.
Oocyte/Embryo Quality	Some analyses suggested a higher proportion of top-quality embryos developed with HP-hMG compared to rFSH, despite rFSH sometimes resulting in a higher number of retrieved oocytes.

Safety Profile in High-Responder Patients

Recent research, including the MEGASET-HR trial, focused on patients considered high responders (those with a higher ovarian reserve). The findings indicated that ovarian stimulation using HP-hMG in this subgroup was associated with a reduced incidence of Ovarian Hyperstimulation Syndrome (OHSS) when compared to rFSH.

Current Research Focus

While multiple large, randomized trials have demonstrated comparable efficacy between HP-hMG and rFSH regarding pregnancy rates, research continues to explore the distinct role of the LH/hCG activity present in HP-hMG. Current investigations are aimed at identifying specific patient profiles that may benefit from the unique hormonal composition of HP-hMG to further personalize ART treatment protocols.

Common questions about Menogon HP (FAQ)

Q: What is Menogon HP and how does it work?

Menogon HP is a medicine that contains highly purified human menopausal gonadotrophin (HMG). According to regulatory documents, HMG contains both luteinizing hormone (LH) activity and follicle stimulating hormone (FSH) activity. Regulatory documents indicate these hormones are necessary for stimulating the ovaries, which is intended to promote the development of mature eggs or sperm production, depending on the indication.

Q: What active ingredients does Menogon HP contain?

The active substance in Menogon HP is human menopausal gonadotrophin (HMG), a hormonal medicine. Official product information states that it is a highly purified form obtained from the urine of postmenopausal women. The specific amounts of FSH and LH activity are measured and expressed in International Units (IU).

Q: What is the primary use of Menogon HP?

Menogon HP is officially indicated for the treatment of infertility in both women and men. In women, official documentation states it is used to stimulate the development of multiple follicles for assisted reproductive technologies. In men, it is used to stimulate spermatogenesis (the production of sperm) in cases of hormonal deficiency, often in combination with human chorionic gonadotrophin (hCG).

Q: Is Menogon HP used for both men and women?

Yes, according to the official product information, Menogon HP has approved uses for both women and men. The medicine is utilized in women undergoing fertility treatments to stimulate the ovaries. For men, it is used as part of a regimen with human chorionic gonadotrophin (hCG) to support the stimulation of sperm production.

Q: How should Menogon HP be stored?

Regulatory documents state that Menogon HP should be stored at a temperature below 25°C. It is specified that the product should be kept in the original package to protect it from light. Official storage information emphasizes that the medicine should be kept out of the sight and reach of children, and it should not be used past the date indicated as the expiration date.

Q: Can Menogon HP be self-administered, or does it need to be given by a doctor?

Menogon HP is administered by either subcutaneous or intramuscular injection. Official information indicates that patients or their partners may receive training to perform these injections at home. However, regulatory guidelines specify that the first administration is generally conducted under the supervision of a physician.

Q: What is the difference between FSH and HMG?

HMG stands for Human Menopausal Gonadotrophin, which is the active ingredient in Menogon HP. According to regulatory sources, HMG contains both Follicle Stimulating Hormone (FSH) activity and Luteinizing Hormone (LH) activity. This means HMG provides the activity of these two different hormones, while some other medicines may contain only FSH.

Q: What does highly purified mean in relation to Menogon HP?

The term highly purified describes the specific manufacturing process used for the HMG in Menogon HP. Regulatory documents confirm that this high level of purification reduces the presence of non-hormonal proteins in the final product. Regulatory documents confirm this purification level is a quality measure to ensure the high standard and consistency of the medicine.

Storage Requirements

Product State	Temperature Requirement	Stability Constraint
Unreconstituted Powder	Store not above 25 C	Must be stored in original container to protect from light
Unopened Pen	Store in refrigerator (2 C–8 C)	Do not freeze
Opened Pen	Store at room temperature (not above 25 C)	Use within a maximum of 28 days after first use
Reconstituted Solution	N/A	Intended for immediate use; discard any remainder

The medicine must be kept out of the sight and reach of children. For the pen formulation, the needle must be removed after each use; do not store the pen with the needle attached.

Disposal Instructions

Any unused product, reconstituted solution, or waste material must be disposed of in accordance with local requirements. Medicines should not be thrown away via wastewater or household waste. Used needles and other sharps must be carefully disposed of.